Zymeworks Wins FDA Approval for Zanidatamab in Biliary Tract Cancer

Vancouver-based Zymeworks (TSX: ZYME; NYSE: ZYME) received full FDA approval on September 3, 2026 for zanidatamab (brand name: Ziihera) as a second-line treatment for adults with HER2-amplified biliary tract cancer (BTC), including cholangiocarcinoma and gallbladder carcinoma. The decision marks the company’s first commercial regulatory win after more than a decade of bispecific antibody pipeline development and follows accelerated approval granted in late 2023 — now converted to full approval on the strength of confirmatory trial data.

The pivotal HERIZON-BTC-01 trial underpinned the submission, showing a confirmed objective response rate (ORR) of 41.3% and a median duration of response of 12.9 months in the HER2-amplified, previously treated population. Crucially, the label covers HER2 immunohistochemistry (IHC) 3+ and IHC 2+/ISH+ patients, broadening the eligible patient pool beyond the most stringent HER2-positive threshold. An estimated 15,000 to 20,000 new BTC diagnoses occur annually in North America, with roughly 20–25% carrying HER2 amplification, translating to approximately 3,500–5,000 newly eligible patients per year in the U.S. alone.

Commercial Opportunity and Peak Sales Potential

Wall Street analysts and buyside consensus peg zanidatamab’s peak annual sales in BTC at USD $650–$800 million globally by 2031, with the broader HER2-targeted opportunity — including gastroesophageal and colorectal indications in Phase 3 — potentially pushing lifetime peak sales above USD $1.4 billion. At the current USD/CAD rate of 1.3925, that translates to roughly CAD $1.95 billion in peak global revenue potential. Zymeworks retains full commercial rights in the U.S. after reacquiring them from Jazz Pharmaceuticals in 2023; partner BeiGene holds rights in Asia. U.S. commercial launch is targeted for Q4 2026, with a list price expected in the USD $18,000–$22,000 per-month range, consistent with HER2-targeted oncology benchmarks.

The competitive landscape is manageable but not empty. Roche’s trastuzumab (Herceptin) and pertuzumab combinations dominate HER2-positive breast and gastric cancers but lack FDA approval specifically in BTC. AstraZeneca’s trastuzumab deruxtecan (T-DXd) is being evaluated in BTC trials, representing the most credible future rival. Zanidatamab’s bispecific mechanism — simultaneously binding HER2 domain IV and domain II — differentiates it mechanistically and may offer activity in patients who progress on monospecific HER2 agents.

Health Canada Review and Canadian Investor Angle

A parallel Health Canada New Drug Submission remains under priority review, with a decision expected in Q1 2027. Canada diagnoses approximately 1,200–1,500 new BTC cases annually, a smaller but meaningful market that would also establish Zymeworks’ commercial infrastructure domestically. Canadian retail investors holding ZYME on the TSX should note that the stock is quoted in CAD and has historically traded at a modest discount to its NYSE-listed USD equivalent due to liquidity differences — the spread can represent a tactical entry point around binary catalysts.

As of market open on September 3, 2026, ZYME shares surged approximately 34% on the NYSE following the approval announcement, reflecting significant short covering alongside long-only accumulation. The XBI biotech ETF climbed 1.21% and IBB rose 1.41% on the same session, providing a constructive sector tailwind. For long-term holders, the thesis has materially de-risked: Zymeworks now transitions from a clinical-stage company to a commercial-stage one with a validated platform, a launched product, and multiple Phase 3 readouts — including gastroesophageal cancer — expected through 2027.